f Post-Approval Studies (PAS) Database
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


Duraloc Long Term

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Redesigned/Replaced Study
Application Number /
Requirement Number
P040023 / PAS001
Date Original Protocol Accepted 05/03/2005
Date Current Protocol Accepted 05/03/2005
Study Name Duraloc Long Term
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives The post-approval study is a prospective, uncontrolled multi-center study that is designed to evaluate the long-term safety and effectiveness of the Duraloc Option Ceramic Hip. However, because of the lack of progress on the original PAS, FDA asked the sponsor to redesign the PAS. The PAS was revised per a FDA letter dated 7/14/09. The new protocol is not approved yet [Aug 13, 2010]. The description presented here is for the old study
Study Population Study population as per device indication. This device is indicated for non-cemented use in primary total hip arthroplasty in skeletally mature patients with non-inflammatory degenerative joint disease (NIDJD) such as osteoarthritis, avascular necrosis, congenital hip dysplasia, and post-traumatic arthritis.
Sample Size A total of 250 patients 10 clinical centers
Key Study Endpoints Key endpoints include device survival, Harris Hip Score, and radiographic assessment. During the final 5 years of patient follow-up, patients will only complete a mailed outcomes questionnaire that will inquire regarding device survival and patient satisfaction.
Follow-up Visits and Length of Follow-up Each patient will be followed for 10 years. During the first 5 years of patient follow-up, patients will undergo clinical and radiographic examination as well as complete an outcomes questionnaire.

Duraloc Long Term Reporting Schedule

Reporting Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
Study Initiation report 11/10/2005 11/10/2005 On Time
1 year report 05/03/2006 07/25/2006 Overdue/Received
2 year report 07/03/2007 07/16/2007 Overdue/Received
Adverse Device Report 01/15/2008 01/15/2008 On Time
3 year report 05/02/2008 05/07/2008 Overdue/Received
4 year report 07/29/2009 08/04/2009 Overdue/Received

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources